Clinical Trial Update: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers [Phase 1]

View source ↗

Summary

Phase 1b study evaluating SL-172154 in combination with other agents in platinum-resistant ovarian, fallopian tube, and primary peritoneal carcinomas has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma
• Platinum-resistant Fallopian Tube Carcinoma
• Platinum-resistant Ovarian Cancer
• Platinum-resistant Primary Peritoneal Carcinoma

Drugs mentioned

• SL-172154 (SIRPα-Fc-CD40L)

Snippet

Sponsor: Shattuck Labs, Inc. | Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-12-23